Page last updated: 2024-10-30

leflunomide and Diffuse Parenchymal Lung Disease

leflunomide has been researched along with Diffuse Parenchymal Lung Disease in 30 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment."7.81Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015)
"Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently."7.73Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006)
"A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide."7.72Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004)
"Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA."6.53Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016)
"Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate."6.45Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009)
"The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern."5.35Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009)
"Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment."3.81Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015)
"A 60-year-old rheumatoid arthritis (RA) female with lung fibrosis was treated with leflunomide (LEF) for only 12 days, and responded well."3.74Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. ( Harada, M; Inokuma, S; Koyama, T; Niiro, H; Ohtani, R; Otsuka, T; Yoshizawa, S, 2008)
"We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide."3.73Leflunomide induced acute interstitial pneumonia. ( Adachi, D; Akiba, H; Akiyama, Y; Hirano, M; Mimura, T; Takeishi, M, 2005)
"Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently."3.73Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006)
"A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide."3.72Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004)
"Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA."2.53Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016)
"The pathogenesis of DMARD-induced lung injury may have common features that need to be clarified in the future."2.47Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. ( Inokuma, S, 2011)
"Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP."2.45Clinical expression of leflunomide-induced pneumonitis. ( Chikura, B; Dawson, JK; Lane, S, 2009)
"Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate."2.45Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009)
"Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)."1.43[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016)
"Leflunomide (LEF)-induced interstitial lung disease (ILD) has been reported in patients with rheumatoid arthritis."1.37Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature. ( Zhang, WX; Zhang, ZQ; Zhao, XW; Zhou, W, 2011)
"The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern."1.35Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (60.00)29.6817
2010's10 (33.33)24.3611
2020's2 (6.67)2.80

Authors

AuthorsStudies
Kim, JW3
Chung, SW3
Pyo, JY3
Chang, SH3
Kim, MU3
Park, CH3
Lee, JS6
Ha, YJ3
Kang, EH3
Lee, YA3
Park, YB3
Lee, EY3
Choe, JY4
Cano-Jiménez, E1
Vázquez Rodríguez, T1
Martín-Robles, I1
Castillo Villegas, D1
Juan García, J1
Bollo de Miguel, E1
Robles-Pérez, A1
Ferrer Galván, M1
Mouronte Roibas, C1
Herrera Lara, S1
Bermudo, G1
García Moyano, M1
Rodríguez Portal, JA1
Sellarés Torres, J1
Narváez, J1
Molina-Molina, M1
Atzeni, F1
Boiardi, L1
Sallì, S1
Benucci, M1
Sarzi-Puttini, P1
Rutanen, J1
Kononoff, A1
Arstila, L1
Elfving, P1
Koskela, H1
Kaipiainen-Seppänen, O1
Maskey-Warzęchowska, M1
Karwat, K1
Szczepankiewicz, B1
Langfort, R1
Szołkowska, M1
Chazan, R1
Keng, LT1
Lin, MW1
Huang, HN1
Chung, KP1
Wang, L1
Yang, Y1
Jia, Y1
Miao, H1
Zhou, YS1
Zhang, XY1
Chikura, B1
Lane, S1
Dawson, JK2
Sawada, T2
Inokuma, S4
Sato, T2
Otsuka, T3
Saeki, Y2
Takeuchi, T2
Matsuda, T2
Takemura, T2
Sagawa, A2
Alcorn, N1
Saunders, S1
Madhok, R1
Wong, SP1
Chu, CM1
Kan, CH1
Tsui, HS1
Ng, WL1
Lee, MA1
Hutchinson, DG1
McLaren, ZL1
Zhang, WX1
Zhou, W1
Zhang, ZQ1
Zhao, XW1
Mohr, M1
Jacobi, AM1
McCurry, J1
Scott, DL1
Ito, S1
Sumida, T1
Kamata, Y1
Nara, H1
Kamimura, T1
Haneda, K1
Iwamoto, M1
Masuyama, J1
Okazaki, H1
Minota, S1
Nakajima, A1
Yamanaka, H1
Sugii, S1
Takeishi, M1
Akiyama, Y1
Akiba, H1
Adachi, D1
Hirano, M1
Mimura, T1
Suissa, S1
Hudson, M1
Ernst, P1
Kudo, S1
Sugiyama, Y1
Chida, K1
Ogura, T1
Yamaguchi, T1
Miyazaki, K1
Ochi, S1
Harigai, M1
Mizoguchi, F1
Iwai, H1
Hagiyama, H1
Oka, T1
Miyasaka, N1
Ju, JH1
Kim, SI1
Lee, JH1
Lee, SI1
Yoo, WH1
Chung, SH1
Lee, J1
Lee, YH1
Lee, SS1
Yoon, HJ1
Yoon, CH1
Kim, HY1
Park, SH1
Koyama, T1
Ohtani, R1
Niiro, H1
Yoshizawa, S1
Harada, M1

Reviews

8 reviews available for leflunomide and Diffuse Parenchymal Lung Disease

ArticleYear
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
    Expert review of clinical immunology, 2013, Volume: 9, Issue:7

    Topics: Antibodies, Blocking; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheum

2013
Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.
    Medicine, 2016, Volume: 95, Issue:26

    Topics: Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom

2016
Clinical expression of leflunomide-induced pneumonitis.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:9

    Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents;

2009
Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
    Drug safety, 2009, Volume: 32, Issue:12

    Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Drug Therapy, Combination;

2009
Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:4

    Topics: Animals; Antirheumatic Agents; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial;

2011
[Leflunomide for therapy of rheumatoid arthritis].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Is

2005
[Adverse effects of DMARDs in treatment of rheumatoid arthritis].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 1

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Hematologic Diseases; H

2005
[Drug induced lung injuries in Japanese population].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Jun-10, Volume: 95, Issue:6

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposi

2006

Other Studies

22 other studies available for leflunomide and Diffuse Parenchymal Lung Disease

ArticleYear
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
    Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male;

2023
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.
    Scientific reports, 2021, 04-28, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies

2021
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
    Scandinavian journal of rheumatology, 2014, Volume: 43, Issue:3

    Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fema

2014
Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis.
    Pneumonologia i alergologia polska, 2015, Volume: 83, Issue:1

    Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Fatal Outcome; Humans; Isoxazoles; Leflunomide; Lung

2015
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, 12-18, Volume: 48, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle

2016
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:9

    Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Weight; Female; Humans; Isoxazoles; Japan; L

2009
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:10

    Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Crotonates

2009
Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:8

    Topics: Adult; Alveolitis, Extrinsic Allergic; Anion Exchange Resins; Antirheumatic Agents; Arthritis, Rheum

2009
HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and normal lung function tests and chest radiography.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:6

    Topics: Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Isoxazoles; Leflunomide; Lung Diseases,

2010
Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:8

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Cause of Death; Humans; Isoxazoles; Japan

2010
Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Child; China; Female; Humans; IgA Vasculitis; Isoxazo

2011
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
    Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchoalveolar Lava

2011
Japan deaths spark concerns over arthritis drug.
    Lancet (London, England), 2004, Feb-07, Volume: 363, Issue:9407

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cause of Death; Drug Approval; Human

2004
Interstitial lung disease and disease modifying anti-rheumatic drugs.
    Lancet (London, England), 2004, Apr-10, Volume: 363, Issue:9416

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz

2004
Interstitial lung disease associated with leflunomide.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lun

2004
Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:12

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Human

2004
Leflunomide induced acute interstitial pneumonia.
    The Journal of rheumatology, 2005, Volume: 32, Issue:6

    Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Cholestyramine Resin; Drug Therapy, Combination; Fema

2005
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:5

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Isoxazoles; Leflunomide

2006
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Jun-10, Volume: 95, Issue:6

    Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomid

2006
Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.
    Modern rheumatology, 2006, Volume: 16, Issue:5

    Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autopsy; Cholestyramine

2006
Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:6

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Korea; Leflunomide; Lung Di

2007
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease.
    Modern rheumatology, 2008, Volume: 18, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female

2008